Aplagon
Helsinki, FI · 1 known investors
Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics targeting thromboinflammatory and cardiovascular diseases. The company's lead candidate, APAC, is a heparin proteoglycan mimetic currently in clinical trials.
BiotechHealthtechMedical Devices
Investors · 1
In the news
- Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development - BioSpacebiospace.com · 2026
- Aplagon Raises €4.8 Million To Broaden Phase 2 Trials Of APAC Therapypulse2.com · 2026
- Aplagon Raises €4.8M in Financingfinsmes.com · 2026
- Aplagon raises €4.8m to expand antithrombotic into new Phase II trial - European Biotechnology Magazineeuropean-biotechnology.com · 2026
- Aplagon secures funding to support Phase IIa trial of APAC therapeuticfinance.yahoo.com · 2025
- Aplagon announces EUR 7 million financing - NLSnordiclifescience.org · 2025